GTP cyclohydrolase 1 gene 3′-UTR C+243T variant predicts worsening outcome in patients with first-onset ischemic stroke

Abstract

Tetrahydrobiopterin (BH4) is an essential cofactor for all three nitric oxide synthase (NOS isoforms), which plays an important role in vascular diseases. GTP cyclohydrolase 1 (GCH 1) is the first-step and rate-limiting enzyme for BH4 biosynthesis in its de novo pathway. Common GCH1 gene variant C+243T in the 3′-untranslated region predicts NO excretion. The present study examined the predictive role of GCH 1 gene 3′-UTR C+243T variant in the long-term outcome of ischemic stroke. A total of 142 patients with first-onset ischemic stroke were recruited and detected for genotype of GCH1 3′-UTR C+243T by a TaqMan SNP Genotyping assay. Subsequent vascular events and death were determined over a 5-year follow-up period. The frequency of GCH1 3′-UTR +243 C/T or T/T genotype was significantly increased in patients with endpoint events as compared with those without events (74% vs 57.8%, P=0.06). Cox regression survival analysis indicated that an increased probability of death or new vascular events was found in patients with GCH1 3′-UTR +243 C/T or T/T genotype compared with those with GCH1 3′-UTR C/C genotype (40.6% vs 25.5%), GCH1 3′-UTR +243 C/T or T/T genotype relative to GCH1 3′-UTR C/C genotype was associated with the increased risk of death or vascular events even after adjustment for other risk factors (OR=2.171, 95% CI: 1.066–4.424, P=0.033). It was concluded that GCH1 3′-UTR C+243T variant was an independent predictor of worsening long-term outcomes in patients with first-onset ischemic stroke.

Keywords

GTP cyclohydrolase 1 / ischemic stoke / outcome / gene polymorphism

References

[1] MurphyS., GibsonC.L.. Nitric oxide, ischaemia and brain inflammation. Biochem Soc Trans, 2007, 35(5): 1133-1137

[2] MoensA.L., KassD.A.. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol, 2006, 26(11): 2439-2444

[3] Scott-BurdenT.. Regulation of nitric oxide production by tetrahydrobiopterin. Circulation, 1995, 91(1): 248-250

[4] AuerbachG., NarH.. The pathway from GTP to tetrahydrobiopterin: threedimensional structures of GTP cyclohydrolase I and 6-pyruvoyl tetrahydropterin synthase. Biol Chem, 1997, 378(3–4): 185-192

[5] HylandK., GunasekaraR.S., Munk-MartinT.L., et al.. The hph-1 mouse: a model for dominantly inherited GTP-cyclohydrolase deficiency. Ann Neurol, 2003, 54(Suppl6): S46-S48

[6] KiddG.A., HongH., MajidA., et al.. Inhibition of brain GTP cyclohydrolase I and tetrahydrobiopterin attenuates cerebral infarction via reducing inducible NO synthase and peroxynitrite in ischemic stroke. Stroke, 2005, 36(12): 2705-2711

[7] ZhangL., RaoF., ZhangK., et al.. Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. J Clin Invest, 2007, 117(9): 2658-2671

[8] AlpN.J., ChannonK.M.. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol, 2004, 24(3): 413-420

[9] WhiteR.P., DeaneC., VallanceP., et al.. Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hypercapnia. Stroke, 1998, 29(2): 467-472

[10] IadecolaC., MoskowitzM.A., LassenN.A.. Nitric oxide synthase inhibition and cerebrovascular regulation. J Cereb Blood Flow Metab, 1994, 4(2): 175-192

[11] WhiteR.P., VallanceP., MarkusH.S.. Effect of inhibition of nitric oxide synthase on dynamic cerebral autoregulation in humans. Clin Sci, 2000, 99(6): 555-560

[12] DraijerR., AtsmaD.E., der vanL.A., et al.. cGMP and nitric oxide modulate thrombin-induced endothelial permeability: regulation via different pathways in human aortic and umbilical vein endothelial cells. Circ Res, 1995, 76(2): 199-208

[13] IgnarroL.J.. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol, 2002, 53(4Pt1): 503-514

[14] HuangP.L.. Nitric oxide and cerebral ischemic preconditioning. Cell Calcium, 2004, 36(3–4): 323-329

[15] ChenJ., ZacharekA., ZhangC., et al.. Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice. J Neurosci, 2005, 25(9): 2366-2375

[16] SunM., ZhaoY., GuY., et al.. Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke. Neurochem Int, 2009, 54(5–6): 339-346

[17] LiuK., LiQ., ZhangL., et al.. The dynamic detection of NO during stroke and reperfusion in vivo. Brain Inj, 2009, 23(5): 450-458

[18] CaiS., AlpN.J., McDonaldD., et al.. GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation. Cardiovasc Res, 2002, 55(4): 838-849

[19] Vasquez-VivarJ., KalyanaramanB., MartasekP., et al.. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA, 1998, 95(16): 9220-9225

[20] PieperG.M.. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol, 1997, 29(1): 8-15

[21] CosentinoF., PattonS., d’UscioL.V., et al.. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest, 1998, 101(7): 1530-1537

[22] StroesE., KasteleinJ., CosentinoF., et al.. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest, 1997, 99(1): 41-46

[23] SetoguchiS., MohriM., ShimokawaH., et al.. Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J Am Coll Cardiol, 2001, 38(2): 493-498

[24] HigmanD.J., StrachanA.M., ButteryL., et al.. Smoking impairs the activity of endothelial nitric oxide synthase in saphenous vein. Arterioscler Thromb Vasc Biol, 1996, 16(4): 546-552

[25] SunH., PatelK.P., MayhanW.G.. Tetrahydrobiopterin, a cofactor for NOS, improves endothelial dysfunction during chronic alcohol consumption. Am J Physiol Heart Circ Physiol, 2001, 281(5): H1863-1869